Navigation Links
Predicting The Risk Of Osteoarthritis

Acetabular dysplasia is a developmental condition, often present at birth. It is marked by a shallow hip pocket and makes the hip unstable. In some extreme cases, it can make the hip prone to dislocation.// A new study reveals the condition acetabular dysplasia is a strong independent indicator for the development of osteoarthritis (OA) of the hip.

Osteoarthritis of the hip is one of the leading causes of disability among the elderly. In addition to severe acetabular dysplasisa, its development is associated with multiple factors, including genes, age, gender, hormones, and body mass index. Results of a recent study has shown that the condition acetabular dysplasia is a strong independent indicator for the development of osteoarthritis (OA) of the hip.

For the study researchers studied 835 seniors. Over a follow-up period averaging six years, participants were examined through radiographs for definite signs of hip OA. It was observed that those with acetabular dysplasia had about a four-times increased risk for OA of the hip and more women than men with acetabular dysplasia had severe hip OA.

Thus in conclusion researchers say acetabular dysplasia is a strong, independent indicator for the development of hip OA.
'"/>




Page: 1

Related medicine news :

1. Predicting The Risk Of Preeclampsia During Pregnancy
2. Predicting The Risk Of A Heart Attack
3. Predicting Severity Of Appendicitis With Computed Tomography
4. Predicting The Risk Of Breast Cancer In The Future
5. Predicting Breast Cancer Recurrence By Understanding Gene Signature
6. Researchers Find Mix of Biomarkers Predicting Mortality
7. Biomarkers Predicting Mortality Found Using Statistical Technique
8. HIV RNA Level Seen As Little Value In Predicting Treatment
9. Predicting the Dynamics of Clotting in Human Blood
10. Follicle Count Test as Good as Hormone Tests in Predicting Ovarian Response
11. New device for discerning Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group Allied ... as new board chair for Orange County health care system CalOptima Friday. CalOptima ... soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of this ...
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today ... Christopher Gabrieli , partner emeritus ... of the board of Akcea Therapeutics. ... Sandford D. Smith , founder and ... are excited to announce this expansion to our board and ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
Breaking Medicine Technology: